Completed PHASE4 INTERVENTIONAL 2-arm NCT02612298

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate (ESAHOM)

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate in Patients With Essential Hypertension

Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd.

Conditions Essential Hypertension

Interventions Arotinolol Hydrochloride Metoprolol succinate sustained-release tablet

Updated 8 times since 2017 Last updated: Apr 15, 2019 Started: Aug 31, 2015 Primary completion: Sep 13, 2018 Completion: Sep 13, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Essential Hypertension and is currently completed. Sumitomo Pharma (Suzhou) Co., Ltd. leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Sep 2022 [monthly]

Completed PHASE4
May 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Jan 2019 — May 2019 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jun 2018 — Jan 2019 [monthly]

Recruiting PHASE4
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sumitomo Pharma (Suzhou) Co., Ltd.

Data source: Sumitomo Pharma (Suzhou) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China